所有图片(1)

主要文件

COO原产地证书/COA分析证书

查看所有文档

安全信息

安全和法规

PHR1043

泼尼松龙

Name: 泼尼松龙
Brand: SIAL

Pharmaceutical Secondary Standard; Certified Reference Material

别名:

1,4-孕甾二烯-11β,17α,21-三醇-3,20-二酮, 1-去氢氢化可的松, 1-去氢皮质醇, 11β,17α,21-三羟基-1,4-孕甾二烯-3,20-二酮

登录查看公司和协议定价

所有图片(1)

About This Item

经验公式（希尔记法）:

C₂₁H₂₈O₅

CAS号:

50-24-8

分子量:

360.44

Beilstein:

1354103

EC 号:

200-021-7

MDL编号:

MFCD00003649

UNSPSC代码:

41116107

PubChem化学物质编号:

329823073

NACRES:

NA.24

推荐产品

Slide 1 of 10

1 of 10

Sigma-Aldrich

P6004

泼尼松龙

Supelco

PHR1042

强的松

Sigma-Aldrich

P6254

强的松

Supelco

PHR1630

醋酸泼尼松龙

Supelco

PHR1014

氢化可的松

Sigma-Aldrich

D4902

地塞米松

USP

1555005

泼尼松龙

Supelco

PHR1012

对羟基苯甲酸甲酯

P2700000

泼尼松龙

Supelco

PHR1041

四环素盐酸盐

等级

certified reference material
pharmaceutical secondary standard

质量水平

300

Agency

traceable to BP 464
traceable to Ph. Eur. P2700000
traceable to USP 1555005

API类

prednisolone

CofA

current certificate can be downloaded

技术

HPLC: suitable
gas chromatography (GC): suitable

mp

240 °C (dec.) (lit.)

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-30°C

SMILES字符串

O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2([H])[C@@H](O)C[C@@]4(C)[C@@]3([H])CC[C@]4(O)C(CO)=O)=C1

InChI

1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

InChI key

OIGNJSKKLXVSLS-VWUMJDOOSA-N

基因信息

human ... NR3C1(2908)

正在寻找类似产品? 访问产品对比指南

一般描述

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Prednisolone is a glucocorticoid utilized as an anti-inflammatory or an immunosuppressive drug.

应用

Prednisolone may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by chromatography techniques.

Prednisolone may be used as a standard in the separation and determination of prednisolone in serum samples of animals using radioimmunoassay.

These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

分析说明

These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.

其他说明

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

附注

To see an example of a Certificate of Analysis for this material enter LRAA6903 in the slot below. This is an example certificate only and may not be the lot that you receive.

警示用语：

Danger

危险声明

H360FD

预防措施声明

P201 - P202 - P280 - P308 + P313 - P405 - P501

危险分类

Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Development and validation of spectrophotometric and HPLC method for the simultaneous estimation of salbutamol sulphate and prednisolone in tablet dosage form

Chitlange SS, et al.

Journal of Analytical and Bioanalytical Techniques , 2(117), 2-2 (2011)

Separation of serum prednisolone and prednisolone-21-hemisuccinate by extraction and their concurrent determination by radioimmunoassay

Yanaglbashl, K, et al.

Clinical Chemistry, 26(9), 1301-1303 (1980)

Quantitative determination of captopril and prednisolone in tablets by FT-Raman spectroscopy

Mazurek S and Szostak R

Journal of Pharmaceutical and Biomedical Analysis, 40(5), 1225-1230 (2006)

Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.

Vappu Rantalaiho et al.

Annals of the rheumatic diseases, 73(11), 1954-1961 (2013-08-03)

To study whether adding initial infliximab to remission-targeted initial combination-DMARD treatment improves the long-term outcomes in patients with early rheumatoid arthritis (RA). Ninety-nine patients with early, DMARD-naïve RA were treated with a triple combination of DMARDs, starting with methotrexate (max

Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.

Axel Heidenreich et al.

European journal of cancer (Oxford, England : 1990), 50(6), 1090-1099 (2014-02-04)

Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel. Subsequently, compassionate-use programmes (CUPs) and expanded-access programmes (EAPs) were established worldwide, allowing access to cabazitaxel before

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

主要文件

安全信息

泼尼松龙

Pharmaceutical Secondary Standard; Certified Reference Material

About This Item

推荐产品

属性

等级

质量水平

Agency

API类

CofA

技术

mp

应用

包装形式

储存温度

SMILES字符串

InChI

InChI key

基因信息

说明

一般描述

应用

分析说明

其他说明

附注

相关产品

相关产品

安全信息

象形图

警示用语：

危险声明

预防措施声明

危险分类

储存分类代码

WGK

法规信息

文件

分析证书(COA)

已有该产品？

同行评审论文

技术服务